TLDR Platelet-rich plasma therapy may help treat folliculitis decalvans but benefits might not last without ongoing treatment.
The document reports on a case series involving two male patients with refractory folliculitis decalvans (FD) who underwent platelet-rich plasma (PRP) therapy. The first patient, aged 36, saw symptomatic improvement and hair loss stabilization after four PRP sessions over four months, but the benefits were not maintained without continuous treatment. The second patient, aged 25, experienced noticeable improvement after three PRP sessions but relapsed when treatment was paused. The study suggests PRP's potential anti-inflammatory and antimicrobial effects could be beneficial for FD treatment but emphasizes the need for larger studies due to the small sample size and temporary nature of the results.
33 citations,
July 2020 in “Journal of The American Academy of Dermatology” PRP treatment improves hair density and thickness for alopecia, but needs more research.
18 citations,
July 2020 in “Journal of The American Academy of Dermatology” PRP injections improve hair density and thickness in women with hair loss.
28 citations,
August 2018 in “Dermatologic Surgery” Platelet-Rich Plasma (PRP) may help improve hair density in primary cicatricial alopecias (PCAs) patients, but more trials are needed to confirm its benefits.
40 citations,
August 2018 in “Journal of the American Academy of Dermatology” Clindamycin and rifampicin are the most effective treatments for folliculitis decalvans, but more research is needed.
14 citations,
May 2018 in “Journal of the American Academy of Dermatology” Platelet-rich plasma might be a new way to treat lichen planopilaris.
112 citations,
July 2008 in “Dermatologic Therapy” Folliculitis decalvans is a rare scalp condition causing scarring hair loss, treated with long-term antibiotics and other medications, but it often comes back and is hard to manage.
5 citations,
June 2021 in “JAAD Case Reports” Platelet-rich plasma therapy may help treat folliculitis decalvans but benefits might not last without ongoing treatment.
10 citations,
October 2019 in “Australasian Journal of Dermatology” Secukinumab effectively treated a difficult case of folliculitis decalvans.